Deletion at 13q21 is associated with aggressive prostate cancers

J. T. Dong, C. Chen, B. G. Stultz, John Tod Isaacs, Jr Frierson H.F.

Research output: Contribution to journalArticle

Abstract

Previous cytogenetic and molecular genetic analyses suggest that the q21 band of chromosome 13 harbors a tumor suppressor gene(s) involved in prostatic carcinogenesis. The precise genetic location, however, has not been defined. In this study, we examined prostate cancer specimens and cell lines/xenograft for genetic deletions at 13q21, using the methods of tissue microdissection and duplex PCR. Deletions at 13q21 were detected in 13 of 147 (9%) prostate cancer samples. Deletion of the same region was also detected in the LNCaP cell line and the PC-82 xenograft of prostate cancer. The overlapping region of deletion in LNCaP and PC-82 spans 3.1 cM or 2.9 cR, which is equivalent to 1-3 Mb. The endothelin receptor B gene, a possible tumor suppressor gene at 13q21, was not located in the region of deletion. Among the 13 prostate neoplasms with deletion at 13q21, 5 were metastases, and 7 were poorly differentiated primary tumors. The only primary tumor that was not poorly differentiated but had deletion occurred in one of the youngest patients (49 years) at diagnosis. These results provide evidence that 13q21 may harbor an unidentified gene(s) whose inactivation occurs in some aggressive carcinomas of the prostate. In addition, this study provides a framework for the cloning and identification of the 13q21 gene(s).

Original languageEnglish (US)
Pages (from-to)3880-3883
Number of pages4
JournalCancer Research
Volume60
Issue number14
StatePublished - Jul 15 2000

Fingerprint

Prostatic Neoplasms
Tumor Suppressor Genes
Heterografts
Endothelin B Receptors
Genes
Cell Line
Chromosomes, Human, Pair 13
Microdissection
Cytogenetics
Organism Cloning
Prostate
Molecular Biology
Neoplasms
Carcinogenesis
Neoplasm Metastasis
Carcinoma
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dong, J. T., Chen, C., Stultz, B. G., Isaacs, J. T., & Frierson H.F., J. (2000). Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Research, 60(14), 3880-3883.

Deletion at 13q21 is associated with aggressive prostate cancers. / Dong, J. T.; Chen, C.; Stultz, B. G.; Isaacs, John Tod; Frierson H.F., Jr.

In: Cancer Research, Vol. 60, No. 14, 15.07.2000, p. 3880-3883.

Research output: Contribution to journalArticle

Dong, JT, Chen, C, Stultz, BG, Isaacs, JT & Frierson H.F., J 2000, 'Deletion at 13q21 is associated with aggressive prostate cancers', Cancer Research, vol. 60, no. 14, pp. 3880-3883.
Dong JT, Chen C, Stultz BG, Isaacs JT, Frierson H.F. J. Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Research. 2000 Jul 15;60(14):3880-3883.
Dong, J. T. ; Chen, C. ; Stultz, B. G. ; Isaacs, John Tod ; Frierson H.F., Jr. / Deletion at 13q21 is associated with aggressive prostate cancers. In: Cancer Research. 2000 ; Vol. 60, No. 14. pp. 3880-3883.
@article{378d0624b82e423eb6ee625d25385ce8,
title = "Deletion at 13q21 is associated with aggressive prostate cancers",
abstract = "Previous cytogenetic and molecular genetic analyses suggest that the q21 band of chromosome 13 harbors a tumor suppressor gene(s) involved in prostatic carcinogenesis. The precise genetic location, however, has not been defined. In this study, we examined prostate cancer specimens and cell lines/xenograft for genetic deletions at 13q21, using the methods of tissue microdissection and duplex PCR. Deletions at 13q21 were detected in 13 of 147 (9{\%}) prostate cancer samples. Deletion of the same region was also detected in the LNCaP cell line and the PC-82 xenograft of prostate cancer. The overlapping region of deletion in LNCaP and PC-82 spans 3.1 cM or 2.9 cR, which is equivalent to 1-3 Mb. The endothelin receptor B gene, a possible tumor suppressor gene at 13q21, was not located in the region of deletion. Among the 13 prostate neoplasms with deletion at 13q21, 5 were metastases, and 7 were poorly differentiated primary tumors. The only primary tumor that was not poorly differentiated but had deletion occurred in one of the youngest patients (49 years) at diagnosis. These results provide evidence that 13q21 may harbor an unidentified gene(s) whose inactivation occurs in some aggressive carcinomas of the prostate. In addition, this study provides a framework for the cloning and identification of the 13q21 gene(s).",
author = "Dong, {J. T.} and C. Chen and Stultz, {B. G.} and Isaacs, {John Tod} and {Frierson H.F.}, Jr",
year = "2000",
month = "7",
day = "15",
language = "English (US)",
volume = "60",
pages = "3880--3883",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Deletion at 13q21 is associated with aggressive prostate cancers

AU - Dong, J. T.

AU - Chen, C.

AU - Stultz, B. G.

AU - Isaacs, John Tod

AU - Frierson H.F., Jr

PY - 2000/7/15

Y1 - 2000/7/15

N2 - Previous cytogenetic and molecular genetic analyses suggest that the q21 band of chromosome 13 harbors a tumor suppressor gene(s) involved in prostatic carcinogenesis. The precise genetic location, however, has not been defined. In this study, we examined prostate cancer specimens and cell lines/xenograft for genetic deletions at 13q21, using the methods of tissue microdissection and duplex PCR. Deletions at 13q21 were detected in 13 of 147 (9%) prostate cancer samples. Deletion of the same region was also detected in the LNCaP cell line and the PC-82 xenograft of prostate cancer. The overlapping region of deletion in LNCaP and PC-82 spans 3.1 cM or 2.9 cR, which is equivalent to 1-3 Mb. The endothelin receptor B gene, a possible tumor suppressor gene at 13q21, was not located in the region of deletion. Among the 13 prostate neoplasms with deletion at 13q21, 5 were metastases, and 7 were poorly differentiated primary tumors. The only primary tumor that was not poorly differentiated but had deletion occurred in one of the youngest patients (49 years) at diagnosis. These results provide evidence that 13q21 may harbor an unidentified gene(s) whose inactivation occurs in some aggressive carcinomas of the prostate. In addition, this study provides a framework for the cloning and identification of the 13q21 gene(s).

AB - Previous cytogenetic and molecular genetic analyses suggest that the q21 band of chromosome 13 harbors a tumor suppressor gene(s) involved in prostatic carcinogenesis. The precise genetic location, however, has not been defined. In this study, we examined prostate cancer specimens and cell lines/xenograft for genetic deletions at 13q21, using the methods of tissue microdissection and duplex PCR. Deletions at 13q21 were detected in 13 of 147 (9%) prostate cancer samples. Deletion of the same region was also detected in the LNCaP cell line and the PC-82 xenograft of prostate cancer. The overlapping region of deletion in LNCaP and PC-82 spans 3.1 cM or 2.9 cR, which is equivalent to 1-3 Mb. The endothelin receptor B gene, a possible tumor suppressor gene at 13q21, was not located in the region of deletion. Among the 13 prostate neoplasms with deletion at 13q21, 5 were metastases, and 7 were poorly differentiated primary tumors. The only primary tumor that was not poorly differentiated but had deletion occurred in one of the youngest patients (49 years) at diagnosis. These results provide evidence that 13q21 may harbor an unidentified gene(s) whose inactivation occurs in some aggressive carcinomas of the prostate. In addition, this study provides a framework for the cloning and identification of the 13q21 gene(s).

UR - http://www.scopus.com/inward/record.url?scp=0034660852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034660852&partnerID=8YFLogxK

M3 - Article

C2 - 10919663

AN - SCOPUS:0034660852

VL - 60

SP - 3880

EP - 3883

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 14

ER -